Table 3.

Predictors of abstract strength ratings †

	Abstract 1 OR 95% CI	Abstract 2 OR 95% CI	Abstract 3 OR 95% CI	Abstract 4 OR 95% CI
High vs low country origin	1.03 0.82 to 1.30	1 0.80 to 1.26	1.16 0.92 to 1.46	0.94 0.74 to 1.18
Male (vs female)	0.93 0.73 to 1.18	0.87 0.68 to 1.10	0.97 0.76 to 1.23	0.87 0.68 to 1.10
41–50 years (vs 21–40)	0.81 0.59 to 1.12	0.71* 0.52 to 0.97	1.01 0.73 to 1.39	0.87 0.64 to 1.20
51–60 years (vs 21–40)	0.79 0.57 to 1.09	0.74 0.54 to 1.03	1.14 0.82 to 1.58	0.77 0.56 to 1.06
61+ years (vs 21–40)	0.76 0.54 to 1.06	0.85 0.60 to 1.19	1.12 0.80 to 1.57	0.82 0.58 to 1.15
Clinical academic credentials (vs academic only)	0.83 0.60 to 1.14	0.65** 0.47 to 0.89	0.95 0.68 to 1.32	0.78 0.57 to 1.08
US born (vs not)	1.06 0.78 to 1.44	0.83 0.62 to 1.13	0.94 0.69 to 1.28	0.89 0.66 to 1.21
Reads research daily (vs <daily)	1.03 0.81 to 1.31	0.94 0.74 to 1.20	0.85 0.67 to 1.08	1.14 0.89 to 1.45
CEPH programme (vs school)	1.12 0.87 to 1.45	1.06 0.82 to 1.36	1.03 0.80 to 1.32	1.38* 1.07 to 1.78
Ivy League institution (vs others)	0.78 0.50 to 1.21	0.67 0.43 to 1.06	1.14 0.73 to 1.78	1.08 0.69 to 1.68
South region (vs Northeast)	0.71 0.50 to 1.00	1.08 0.77 to 1.52	0.84 0.59 to 1.18	1.05 0.74 to 1.47
Midwest region (vs Northeast)	0.82 0.55 to 1.23	1.17 0.78 to 1.74	1.14 0.76 to 1.71	1.07 0.72 to 1.59
West region (vs Northeast)	0.93 0.59 to 1.46	1.11 0.72 to 1.74	1.05 0.66 to 1.67	0.89 0.56 to 1.40
60–<120 s spent reading (vs <60 s)	0.67** 0.51 to 0.87	0.87 0.66 to 1.15	0.98 0.74 to 1.28	1.33* 1.04 to 1.70
120+ s spent reading (vs <60 s)	0.49*** 0.34 to 0.71	0.77 0.56 to 1.07	0.65* 0.46 to 0.92	1.63* 1.06 to 2.51
N‡	895	895	895	895

*p<0.05; **p<0.01; ***p<0.001.

†Generalised ordered logit model controlling for all variables in each column.

‡Only survey responses with no missing data included in the multivariate analysis.

Abstract 1, RCT/Service; Abstract 2, Cross-sectional/Service; Abstract 3, RCT/Pharmaceutical; Abstract 4, Cross-sectional/Pharmaceutical.

RCT, randomised controlled trial.